Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyOscar Health GGT Testing Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Gamma-glutamyl Transferase Testing in Adults

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage criteria for serum gamma-glutamyl transferase (GGT) testing in individuals age 18 or older, including covered clinical indications, frequency limits, and testing that does not meet criteria during asymptomatic wellness or general examinations without abnormal findings.

    Policy Summary
    PayerOscar Health
    PolicyGamma-glutamyl Transferase Testing in Adults
    Policy CodePolicy N/A
    Change TypeNon-material update
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and code claims appropriately under applicable industry-standard coding and billing guidelines.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was updated with revised background, guidelines and recommendations, and evidence-based scientific references.

    18+Minimum age
    Every 2 weeksMaximum frequency
    15Qualifying indications
    Not coveredAsymptomatic wellness testing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Eligibility and Coverage Criteria

    Covered adult indications

    Covered when the individual is age 18 or older, the applicable indication is present, and testing is performed no more than once every two weeks.

    ONE of the following covered indications

    • Elevated alkaline phosphatase

      • ALL of the following

        • The individual has elevated alkaline phosphatase activity.
        • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks
    • Assessment of liver injury, function, and/or disease

      • ALL of the following

        • The purpose of testing is to assess liver injury, liver function, and/or liver disease.
        • At least one qualifying condition

          • The individual has chronic alcohol use.
          • The individual is receiving long-term drug therapy known to have potential for liver toxicity.
          • The individual has been exposed to hepatotoxins.
          • The individual has viral hepatitis, amoebiasis, tuberculosis, psittacosis, or a similar infection that may cause hepatic injury.
          • The individual has a primary or secondary malignant neoplasm of the digestive system.

    The coverage criteria apply only to individuals 18 years of age or older. They do not apply to individuals younger than 18 years of age.

    Serum GGT testing for an asymptomatic individual during a wellness visit or general examination, when there are no abnormal findings, does not meet criteria.

    Testing performed during a wellness visit or general examination for an asymptomatic individual without abnormal findings does not meet coverage criteria.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82977Glutamyltransferase, gamma (GGT)

    Documentation and Billing Responsibilities

    Documentation Required

    Submit accurate documentation

    Submit accurate documentation of the services performed and code claims appropriately according to applicable industry-standard coding and billing guidelines.

    Denial Risk

    Avoid asymptomatic wellness testing

    Serum GGT testing for an asymptomatic individual during a wellness visit or general examination without abnormal findings does not meet criteria and is not covered under this policy.

    Denial Risk

    Follow documentation and coding requirements

    Claims may be denied or payment recouped when services are not accurately documented or when applicable coding and billing guidelines are not followed.

    Clinical Background

    Gamma-glutamyl transferase (GGT), also known as gamma-glutamyl transpeptidase, is a cell-surface enzyme found in multiple tissues and is particularly abundant in the liver. Additional concentrations are found in the intestine, kidney, prostate, and pancreas. Serum GGT is commonly used as an aid in evaluating liver and biliary disease, alcohol consumption, and hepatic injury, but it is not highly specific for a particular liver disease. Because GGT is not found in bone, it can help determine whether an elevated alkaline phosphatase level is more likely hepatic rather than bone in origin. Medication use, including phenytoin and phenobarbital, may affect GGT levels or cause false elevations.

    Key Definitions

    Metabolic syndrome
    DefinitionA group of conditions that includes high blood sugar, high blood pressure, obesity, and abnormal cholesterol levels.
    Associated risksMetabolic syndrome collectively increases the risk of heart disease, stroke, type 2 diabetes, and neurologic disorders.
    GGT relevanceGGT has been identified as a biomarker for metabolic syndrome risk.
    Cerebrovascular accident
    DefinitionA cerebrovascular accident (CVA), or stroke, occurs when a blood vessel leading to the brain ruptures or is blocked by a blood clot.
    Transient ischemic attackA temporary blood-vessel blockage affecting part of the brain; symptoms last only a few minutes.

    Clinical Indications for Covered Testing

    Elevated alkaline phosphatase activity

    Covered when the following criterion is met and testing is performed no more than once every two weeks.

    ALL of the following

    • The individual has elevated alkaline phosphatase activity.
    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Assessment of liver injury, liver function, and/or liver disease

    Covered for an adult when the purpose is to assess liver injury, liver function, and/or liver disease, at least one qualifying condition is present, and testing is performed no more than once every two weeks.

    ALL of the following

    Testing Frequency

    Frequency limit
    TestSerum gamma-glutamyl transferase (GGT).
    Maximum frequencyNo more than once every two weeks.
    Applicable populationThe criteria apply to individuals 18 years of age or older.

    Testing Outside Coverage Criteria

    Serum GGT testing during a wellness visit or general examination for an asymptomatic individual without abnormal findings is not covered under these criteria.

    Use of GGT as a screening test for underlying liver disease in the absence of other abnormal liver chemistries is not covered. GGT should not be relied on alone to diagnose alcoholic liver disease or to distinguish among causes of liver disease.

    GGT is not covered when used alone as a diagnostic marker or as screening in the absence of other abnormal liver chemistries. Its clinical interpretation should be integrated with other liver tests and, when appropriate, noninvasive fibrosis testing; GGT alone cannot establish alcoholic liver disease or differentiate all causes of liver disease.

    Policy Summary
    PayerOscar Health
    PolicyGamma-glutamyl Transferase Testing in Adults
    Policy CodePolicy N/A
    Change TypeNon-material update
    Effective DateJan 1, 202744d
    Last ReviewSep 28, 2026
    Next Review DateN/A
    Key ActionSubmit accurate documentation and code claims appropriately under applicable industry-standard coding and billing guidelines.
    SourceLink
    On This Page
    Eligibility and Coverage CriteriaApplicable Procedure CodesDocumentation and Billing ResponsibilitiesClinical BackgroundKey DefinitionsClinical Indications for Covered TestingTesting FrequencyTesting Outside Coverage Criteria
    The individual has diabetes mellitus.
  1. The individual has malnutrition.
  2. The individual has a disorder of iron and mineral metabolism.
  3. The individual has sarcoidosis.
  4. The individual has amyloidosis.
  5. The individual has lupus.
  6. The individual has hypertension.
  7. The individual has gastrointestinal disease.
  8. The individual has pancreatic disease.
  9. Liver function is being assessed subsequent to liver transplantation.
  10. Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks
  11. Ischemic and hemorrhagic strokeAn ischemic stroke occurs when an artery in the brain is completely blocked; a hemorrhagic stroke occurs when a ruptured blood vessel causes bleeding in the brain.
    Drug-induced liver injury (DILI)
    DefinitionDrug-induced liver injury (DILI) is liver damage or dysfunction caused by a drug.
    Standard analytesALT, alkaline phosphatase (ALP), and total bilirubin are the standard analytes used to define liver damage and liver dysfunction in DILI.
    Additional laboratory considerationAST may substitute for ALT when ALT is unavailable at DILI recognition; GGT is less reliable as a substitute for ALP.
    Alcohol-related liver disease (ALD)
    DefinitionAlcohol-related liver disease (ALD) is liver disease associated with alcohol use.
    Indirect markersGGT, ALT, AST, and mean corpuscular volume (MCV) are commonly used markers for early detection of ALD.
    Interpretation limitationThese laboratory values are indirect markers with low sensitivity and specificity; no single marker or combination can differentiate among all causes of liver disease.
    Laboratory-developed test (LDT)
    DefinitionA laboratory-developed test (LDT) is developed, validated, and performed in-house by a laboratory.
    Regulatory frameworkLDTs are regulated by the Centers for Medicare and Medicaid Services (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).
    FDA statusLDTs are not approved or cleared by the U.S. Food and Drug Administration; FDA clearance or approval is not currently required for clinical use.
    Gamma-glutamyl transferase (GGT)
    DefinitionGamma-glutamyl transferase (GGT) is a laboratory marker used to assess certain aspects of alcohol use and hepatic function.
    Recent heavy alcohol useASAM recommends measuring GGT with ALT to identify recent heavy alcohol use and risk for alcohol withdrawal.
    Urine testingWhen conducting a urine test, GGT is recommended as the marker of heavy alcohol consumption.
    The purpose of testing is to assess liver injury, liver function, and/or liver disease.
  12. At least one qualifying condition

    • The individual has chronic alcohol use.
    • The individual is receiving long-term drug therapy known to have potential for liver toxicity.
    • The individual has been exposed to hepatotoxins.
    • The individual has viral hepatitis, amoebiasis, tuberculosis, psittacosis, or a similar infection that may cause hepatic injury.
    • The individual has a primary or secondary malignant neoplasm of the digestive system.
    • The individual has diabetes mellitus.
    • The individual has malnutrition.
    • The individual has a disorder of iron and mineral metabolism.
    • The individual has sarcoidosis.
    • The individual has amyloidosis.
    • The individual has lupus.
    • The individual has hypertension.
    • The individual has gastrointestinal disease.
    • The individual has pancreatic disease.
    • Liver function is being assessed subsequent to liver transplantation.
  13. Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks
  14. Clarification of elevated alkaline phosphatase

    Covered as a clarifying test for an elevated alkaline phosphatase when performed no more than once every two weeks.

    ALL of the following

    • The individual has an elevated alkaline phosphatase level, particularly an isolated elevation or an elevation with normal AST, ALT, and bilirubin, or the hepatic origin is uncertain.
    • Serum GGT is measured to confirm hepatic origin or help distinguish liver alkaline phosphatase from non-liver sources.

      If GGT is elevated when AST, ALT, and bilirubin are normal, liver ultrasound should be ordered.

    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Evaluation of abnormal liver screening tests

    Covered for evaluation of an abnormal liver screening test when GGT is used with the other recommended liver biochemical tests.

    ALL of the following

    • At least one liver screening test is abnormal: ALT, AST, or alkaline phosphatase.
    • GGT is obtained with albumin, bilirubin, and either prothrombin time (PT) or international normalized ratio (INR).

      Direct bilirubin should be included when total bilirubin is elevated.

    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Complementary assessment of alcohol use and withdrawal risk

    Covered as a complementary assessment of alcohol use or withdrawal risk; GGT should not be used alone to establish alcoholic liver disease.

    ALL of the following

    • A relevant alcohol-related assessment is needed

      • The purpose is to assess alcohol use or patterns of alcohol misuse.
      • The purpose is to assess recent heavy alcohol use.
      • The purpose is to assess risk for alcohol withdrawal.
    • GGT is used as a complementary test and not as the sole basis for diagnosing alcoholic liver disease.
    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Assessment of liver disease or fibrosis

    Covered when GGT is assessed with other liver tests and, when appropriate, noninvasive fibrosis testing.

    ALL of the following

    • The purpose is to assess liver disease or fibrosis.
    • GGT is obtained together with other liver tests, including appropriate assessment with ALT and AST.

      GGT is an indirect marker with limited sensitivity and specificity and should not be interpreted as a stand-alone test.

    • Use appropriate additional assessment

      • Noninvasive fibrosis testing is performed when clinically appropriate, such as transient elastography.
      • The clinical evaluation does not require additional noninvasive fibrosis testing at that time.
    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Evaluation of recent heavy alcohol use and withdrawal risk

    Covered when GGT is measured with ALT for this assessment.

    ALL of the following

    • A relevant alcohol-related assessment is needed

      • The purpose is to evaluate recent heavy alcohol use.
      • The purpose is to assess risk for alcohol withdrawal.
    • GGT and ALT are measured together.
    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks

    Initial investigation of potential liver disease or abnormal liver blood tests

    Covered as part of the initial investigation of potential liver disease or abnormal liver blood tests.

    ALL of the following

    • The purpose is the initial investigation of potential liver disease or abnormal liver blood tests.
    • GGT is included with bilirubin, albumin, ALT, and alkaline phosphatase.

      A full blood count is also recommended if it has not been performed within the previous 12 months.

    • Serum GGT testing is performed no more than once every two weeks.No more than once every two weeks